Insider Buying: NewAmsterdam Pharma Company N.V. (NASDAQ:NAMS) Director Purchases 8,584 Shares of Stock

NewAmsterdam Pharma Company N.V. (NASDAQ:NAMS - Get Free Report) Director James N. Topper purchased 8,584 shares of the company's stock in a transaction that occurred on Monday, June 16th. The shares were purchased at an average price of $19.50 per share, for a total transaction of $167,388.00. Following the purchase, the director now directly owns 3,022,153 shares in the company, valued at $58,931,983.50. The trade was a 0.28% increase in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink.

NewAmsterdam Pharma Price Performance

NASDAQ:NAMS traded down $0.24 during trading hours on Friday, reaching $17.96. 1,005,901 shares of the company were exchanged, compared to its average volume of 699,446. The firm has a market cap of $2.02 billion, a price-to-earnings ratio of -9.55 and a beta of -0.03. NewAmsterdam Pharma Company N.V. has a 52-week low of $14.06 and a 52-week high of $27.29. The stock has a 50 day simple moving average of $18.51 and a 200 day simple moving average of $20.82.

NewAmsterdam Pharma (NASDAQ:NAMS - Get Free Report) last issued its earnings results on Thursday, May 8th. The company reported ($0.49) earnings per share for the quarter, missing the consensus estimate of ($0.45) by ($0.04). The firm had revenue of $2.98 million during the quarter, compared to analysts' expectations of $1.46 million. NewAmsterdam Pharma had a negative return on equity of 37.34% and a negative net margin of 397.45%. On average, analysts predict that NewAmsterdam Pharma Company N.V. will post -1.75 EPS for the current fiscal year.

Analysts Set New Price Targets

NAMS has been the topic of several research reports. Needham & Company LLC reissued a "buy" rating and set a $40.00 price objective on shares of NewAmsterdam Pharma in a research report on Thursday, June 12th. Stifel Nicolaus initiated coverage on NewAmsterdam Pharma in a report on Tuesday, June 10th. They set a "buy" rating and a $44.00 price target on the stock. Cantor Fitzgerald initiated coverage on NewAmsterdam Pharma in a report on Wednesday, June 4th. They set an "overweight" rating and a $42.00 price target on the stock. Citigroup initiated coverage on NewAmsterdam Pharma in a research note on Tuesday. They issued a "buy" rating and a $42.00 target price on the stock. Finally, Wall Street Zen downgraded NewAmsterdam Pharma from a "hold" rating to a "sell" rating in a research note on Saturday. One investment analyst has rated the stock with a sell rating and eight have issued a buy rating to the stock. According to MarketBeat, NewAmsterdam Pharma has a consensus rating of "Moderate Buy" and a consensus target price of $42.89.

Hedge Funds Weigh In On NewAmsterdam Pharma

Large investors have recently modified their holdings of the company. Quarry LP purchased a new position in NewAmsterdam Pharma in the first quarter valued at approximately $25,000. GF Fund Management CO. LTD. bought a new stake in shares of NewAmsterdam Pharma in the fourth quarter worth $50,000. National Bank of Canada FI bought a new stake in shares of NewAmsterdam Pharma in the fourth quarter worth $51,000. Mirae Asset Global Investments Co. Ltd. increased its stake in shares of NewAmsterdam Pharma by 19.4% in the first quarter. Mirae Asset Global Investments Co. Ltd. now owns 3,675 shares of the company's stock worth $80,000 after buying an additional 596 shares during the last quarter. Finally, Zurcher Kantonalbank Zurich Cantonalbank increased its position in shares of NewAmsterdam Pharma by 130.4% in the 1st quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 5,990 shares of the company's stock worth $123,000 after purchasing an additional 3,390 shares during the last quarter. 89.89% of the stock is currently owned by hedge funds and other institutional investors.

About NewAmsterdam Pharma

NewAmsterdam Pharma Company N.V., a late-stage biopharmaceutical company, develops therapies to enhance patient care in populations with metabolic disease. It is developing obicetrapib, an oral low-dose cholesteryl ester transfer protein (CETP) inhibitor, that is in various clinical trials as a monotherapy and a combination therapy with ezetimibe for lowering LDL-C for cardiovascular diseases.